Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer

  • D. Tiberi Universite de Montreal
  • P. Vavassis Hopital Maisonneuve-Rosemont
  • D. Nguyen Hopital Maisonneuve-Rosemont
  • M. C. Guilbert Hopital Maisonneuve-Rosemont
  • A. Simon-Cloutier
  • P. Dube
  • M. K. Gervais
  • L. Sideris
  • G. Leblanc
  • T. Hijal
  • M. P. Dufresne
  • M. Yassa
Keywords: Breast cancer, Preoperative radiotherapy, SBRT, SABR, Radiosurgery, Ablative radiotherapy



Standard treatment for early-stage invasive breast cancer consists of breast-conserving surgery (BCS)

and several weeks of adjuvant radiotherapy (RT). Neoadjuvant single-fraction RT is a novel approach for

early-stage breast cancer. We sought to investigate the effect of delaying surgery after neoadjuvant RT

with respect to the rates pathological response (PR).


Materials and Methods

Women aged 65 years or older with a new diagnosis of stage I, luminal A, breast cancer were eligible for

inclusion. A single dose of 20 Gy to the primary breast tumor was given followed by BCS 3 months later.

The primary endpoint was the rate of PR as assessed by microscopic evaluation using the Miller-Payne




10 patients were successfully treated to date. The median age of the patients was 72 years (65-84). 8 patients had a pathological tumor response (PR) to neoadjuvant RT with a median residual cellularity of 3%. No immediate RT complications were noted other than mild dermatitis.


This study demonstrates a method for delivering single fraction RT that can lead to high levels of PR in most patients. Continued accrual of this study and subsequent trials are needed to determine the feasibility, safety and role of this novel technique in the management of early-stage breast cancer.


How to Cite
Tiberi, D., Vavassis, P., Nguyen, D., Guilbert, M. C., Simon-Cloutier, A., Dube, P., Gervais, M. K., Sideris, L., Leblanc, G., Hijal, T., Dufresne, M. P., & Yassa, M. (2020). Tumour response 3 months after neoadjuvant single-fraction radiotherapy for low-risk breast cancer. Current Oncology, 27(3). https://doi.org/10.3747/co.27.6059
Short Communication